[1]李洁茹,李 婉,徐晓坤,等.多发性骨髓瘤患者外周血VCAN mRNA，CCND1 mRNA表达水平与病情进展及预后的相关性研究[J].现代检验医学杂志,2025,40(02):24-29.[doi:10.3969/j.issn.1671-7414.2025.02.005]
　LI Jieru,LI Wan,XU Xiaokun,et al.Correlation between VCAN mRNA and CCND1 mRNA Expression Levels in Peripheral Blood of Patients with Multiple Myeloma and Disease Progression and Prognosis[J].Journal of Modern Laboratory Medicine,2025,40(02):24-29.[doi:10.3969/j.issn.1671-7414.2025.02.005]
点击复制

多发性骨髓瘤患者外周血VCAN mRNA，CCND1 mRNA表达水平与病情进展及预后的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年02期
页码:
24-29
栏目:
论著
出版日期:
2025-03-15

文章信息/Info

Title:
Correlation between VCAN mRNA and CCND1 mRNA Expression Levels in Peripheral Blood of Patients with Multiple Myeloma and Disease Progression and Prognosis
文章编号:
1671-7414（2025）02-024-06
作者:
李洁茹; 李 婉; 徐晓坤; 马圣宇
（安徽医科大学附属宿州医院/ 安徽省宿州市立医院血液内科，安徽宿州 234000）
Author(s):
LI Jieru; LI Wan; XU Xiaokun; MA Shengyu
（Department of Hematology，Suzhou Hospital of Anhui Medical University /Suzhou Municipal Hospital of Anhui Province，Anhui Suzhou 234000，China）
关键词:
多发性骨髓瘤; 多功能蛋白聚糖; 细胞周期蛋白D1
分类号:
R733.3；R730.43
DOI:
10.3969/j.issn.1671-7414.2025.02.005
文献标志码:
A
摘要:
目的 探讨外周血多功能蛋白聚糖（VCAN）、细胞周期蛋白D1（CCND1）水平与多发性骨髓瘤（MM）病情进展及预后的关系。方法 选择2018 年1 月～ 2022 年5 月宿州市立医院血液内科收治的121 例初次诊断MM患者（MM组）和109 例健康志愿者（对照组），根据国际分期系统（ISS）将MM 患者分为Ⅰ期组（n=46）、Ⅱ期组（n=41）和Ⅲ期组（n=34）。实时荧光定量聚合酶链反应（RT-PCR）检测外周血VCAN mRNA，CCND1 mRNA 表达水平，出院后随访24 个月，统计MM患者生存情况。比较不同ISS 分期MM患者外周血VCAN mRNA，CCND1 mRNA 表达水平的差异。Kaplan-Meier 法绘制MM 生存曲线，建立多因素COX 风险比例回归分析影响MM 患者预后的因素。结果 MM 组外周血VCAN mRNA（2.69±0.63），CCND1 mRNA（3.29±0.63）表达水平均高于对照组(1.32±0.46，1.53±0.37)，差异具有统计学意义（t=18.659，25.473，均P ＜ 0.05）。Ⅲ期组外周血VCAN mRNA（3.05±0.31），CCND1 mRNA（3.75±0.21）表达水平高于Ⅱ期组（2.76±0.31，3.29±0.36），Ⅰ期组（2.36±0.25，2.95±0.29），差异具有统计学意义（t=7.626 ～ 16.831，均P ＜ 0.05）。随访期间失访1 例，死亡36 例，存活84 例。VCAN mRNA（57.63%），CCND1 mRNA（56.67%）高表达MM患者总生存率低于VCAN mRNA（81.63%），CCND1 mRNA（83.33%）低表达，差异具有统计学意义（χ2=8.727，10.820，均P ＜ 0.05）。死亡组年龄大于生存组（t=3.020），ISS Ⅲ期、骨髓浆细胞比例≥ 60%，染色体核型1q21+ 比例、外周血VCAN mRNA，CCND1 mRNA 表达均高于生存组（t/χ2=5.988 ～ 8.589），差异具有统计学意义（均P ＜ 0.05）。多因素COX 风险比例分析，ISS Ⅲ期、高表达VCAN mRNA，高表达CCND1 mRNA 是MM 患者随访期间死亡的危险因素（Wald χ2=10.672，5.682，5.969，均P ＜ 0.05）。结论 MM 患者外周血中VCAN mRNA，CCND1 mRNA 表达显著增高，且与高临床分期和不良预后有关。
Abstract:
Objective To investigate the relationship between the levels of Versican (VCAN) and Cyclin D1 (CCND1) in peripheral blood and the progression and prognosis of multiple myeloma (MM). Methods A total of 121 patients with MM (MM group) and 109 healthy volunteers (control group) were selected and admitted to the Department of Hematology of Suzhou Municipal Hospital from January 2018 to May 2022. According to the International Staging System (ISS), the patients with MM were divided into a stage I group（n=46）, a stage II group（n=41）, and a stage III group（n=34）. Real time fluorescence quantitative PCR (RT-PCR) was used to detect the expression levels of VCAN mRNA and CCND1 mRNA in peripheral blood， the patients were followed up for 24 months after discharge to make statistics on the survival of MM patients. The VCAN mRNA and CCND1 mRNA expression in the peripheral blood of MM patients with different ISS was compared. Kaplan-Meier method was used to draw the survival curve of MM, and multi-factor COX proportional regression analysis was established to analyze the factors affecting the prognosis of MM patients. Results The expressions of VCAN mRNA （2.69±0.63）and CCND1 mRNA（3.29±0.63）in peripheral blood of MM group were higher than those of control group (1.32 ± 0.46, 1.53 ± 0.37)， and the differences were statistically significant (t=18.659，25.473，all P<0.05). The expressions of VCAN mRNA(3.05 ± 0.31) and CCND1 mRNA (3.75 ± 0.21) in peripheral blood of stage Ⅲ group were higher than those of stage Ⅱ (2.76 ± 0.31, 3.29 ± 0.36) and stage Ⅰ groups (2.36 ± 0.25, 2.95 ± 0.29), and the differences were statistically significant (t=7.626 ～ 16.831, all P<0.05). During the follow-up period, 1 case was lost to follow-up, 36 cases died and 84 cases survived. The overall survival rate of patients with high VCAN mRNA(58.06%) and CCND1 mRNA (57.14%) expression MM was lower than that of patients with low VCAN mRNA(82.76%) and CCND1 mRNA (84.21%), and the differences were statistically significant (χ2=8.727，10.820， all P < 0.05).The age of the death group was higher than that of the survival group (t=3.020), ISS stage III, and bone marrow cells proportion ≥ 60%, chromosome karyotype 1q21+ proportion, peripheral blood VCAN mRNA and CCND1 mRNA i expression were all higher than those of the survival group (t/χ2=5.988 ～ 8.589)，and the differences were statistically significant (all P<0.05)，respectively. Multivariate COX risk ratio analysis, ISS stage III，high expression of VCAN mRNA and CCND1 mRNA were risk factors for death in MM patients during follow-up (Wald χ2=10.672, 5.682, 5.969, all P<0.05). Conclusion The expression of VCAN mRNA and CCND1 mRNA in peripheral blood of MM patients is significantly increased, which is related to high clinical stage and poor prognosis.

参考文献/References:

[1] 何进, 张艳, 申娴娟, 等. 多发性骨髓瘤患者血清可溶性PD-L1 水平在辅助诊断及临床分型的价值研究[J]. 现代检验医学杂志,2021,36(2):15-18, 110. HE Jin, ZHANG Yan, SHEN Xianjuan, et al. Value of blood soluble PD-L1 in the auxiliary diagnosis and clinical subtype of multiple myeloma[J]. Journal of Modern Laboratory Medicine, 2021, 36(2): 15-18, 110.
[2] PADALA S A, BARSOUK A, BARSOUK A, et al. Epidemiology, staging, and management of multiple myeloma[J]. Medical Sciences(Basel Switzerland), 2021, 9(1): 3.
[3] PAPADAS A, ARAUZ G, CICALA A, et al. Versican and versican-matrikines in cancer progression, inflammation, and immunity [J]. the Journal of Histochemistry & Cytochemistry, 2020, 68(12): 871-885.
[4] KATO K, FUKAI M, HATANAKA K C, et al. Versican secreted by cancer-associated fibroblasts is a poor prognostic factor in hepatocellular carcinoma[J]. Annals of Surgical Oncology, 2022, 29(11): 7135-7146.
[5] NIE Min, WANG Yadong, YU Zenong, et al. AURKB promotes gastric cancer progression via activation of CCND1 expression[J]. Aging (Albany NY), 2020, 12(2): 1304-1321.
[6] ZHU Dawei, HUANG Jie, LIU Ning, et al. PSMC2/CCND1 axis promotes development of ovarian cancer through regulating cell growth, apoptosis and migration[J]. Cell Death & Disease, 2021, 12(8): 730.
[7] 中国医师协会血液科医师分会, 中华医学会血液学分会, 中国医师协会多发性骨髓瘤专业委员会. 中国多发性骨髓瘤诊治指南(2017 年修订)[J]. 中华内科杂志,2017,56(11):866-870. Chinese Hematology Association,Chinese Society of Hematology,Chinese Myeloma Committee-Chinese Hematology Association. The guidelines for the diagnosis and management of multiple myeloma in China (2017 revision) [J]. Chinese Journal of Internal Medicine, 2017, 56(11): 866-870.
[8] GREIPP P R, SAN MIGUEL J, DURIE B G M, et al. International staging system for multiple myeloma[J].Journal of Clinical Oncology, 2005, 23(15): 3412-3420.
[9] WALLINGTON-BEDDOE C T, MYNOTT R L. Prognostic and predictive biomarker developments in multiple myeloma[J]. Journal of Hematology & Oncology, 2021, 14(1): 151.
[10] ZHOU Fan, WANG Dongjiao, WEI Wei, et al. Comprehensive profiling of circular RNA expressions reveals potential diagnostic and prognostic biomarkers in multiple myeloma[J]. BMC Cancer, 2020, 20(1): 40.
[11] CHANG Wenjing, ZHU Jichao, YANG Dianyu, et al. Plasma versican and plasma exosomal versican as potential diagnostic markers for non-small cell lung cancer[J]. Respiratory Research, 2023, 24(1): 140.
[12] SONG Junquan, WEI Rongyuan, HUO Shiying, et al. Versican enrichment predicts poor prognosis and response to adjuvant therapy and immunotherapy in gastric cancer[J]. Frontiers in Immunology, 2022, 13: 960570.
[13] YAMAUCHI N, KANKE Y, SAITO K, et al. Stromal expression of cancer-associated fibroblast-related molecules, versican and lumican, is strongly associated with worse relapse-free and overall survival times in patients with esophageal squamous cell carcinoma[J].Oncology Letters, 2021, 21(6): 445.
[14] LIN Liang, ZHANG Xinwei, CAO Li, et al. Reelin promotes adhesion of multiple myeloma cells to bone marrow stromal cells via integrin β1 signaling[J].Journal of Cancer, 2017, 8(12): 2212-2222.
[15] GUPTA N, KUMAR R, SETH T, et al. Targeting of stromal versican by miR-144/199 inhibits multiple myeloma by downregulating FAK/STAT3 signalling[J].RNA Biology, 2020, 17(1): 98-111.
[16] CHEN Hong, ZHAO Yuan, ZHANG Jiajia, et al. Promoting effects of miR-135b on human multiple myeloma cells via regulation of the Wnt/β-catenin/versican signaling pathway [J]. Cytokine, 2021, 142:155495.
[17] MEI Chao, WANG Tian, XU Baoli, et al. Association of CCND1 rs9344 polymorphism with lung cancer susceptibility and clinical outcomes: a case-control study[J]. BMC Pulmonary Medicine, 2024, 24(1): 167.
[18] YAN Xiao, GAO Minjie, ZHANG Ping, et al. MiR-181a functions as an oncogene by regulating CCND1 in multiple myeloma[J]. Oncology Letters, 2020, 20(1): 758-764.
[19] JIANG Yuwen,ZHANG Chenlu,LU Ling, et al. The prognostic role of cyclin D1 in multiple myeloma: a systematic review and meta-analysis [J].Technology in Cancer Research Treatment,2022, 21:15330338211065252.

相似文献/References:

[1]韩秀蕊,杨娣娣,李艳春,等.多发性骨髓瘤患者骨髓涂片与骨髓活检同步检查的比较分析[J].现代检验医学杂志,2015,30(03):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
　HAN Xiu-rui,YANG Di-di,LI Yan-chun,et al.Comparative Analysis of Bone Marrow Smears and Biopsies Synchronous Check for Myeloma Patients[J].Journal of Modern Laboratory Medicine,2015,30(02):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
[2]邱 爽,孟瑞芳,蒋筱漪,等.血清免疫固定电泳、蛋白电泳、免疫球蛋白及轻链定量在诊断多发性骨髓瘤中的临床应用[J].现代检验医学杂志,2015,30(02):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
　QIU Shuang,MENG Rui-fang,JIANG Xiao-yi,et al.Clinical Application of Immunofixtion Electrophoresis, Serum Protein Electrophoresis and Immunoglobulins and Light Chain Quantitative Analysis in the Diagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2015,30(02):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
[3]李 瑛,李 军.多发性骨髓瘤患者血清中IL-6与IL-27水平监测的临床应用[J].现代检验医学杂志,2016,31(04):87.[doi:10.3969/j.issn.16717-414.2016.04.023]
　LI Ying,LI Jun.Clinical Application of Monitoring IL-6 and IL-27 Levels in Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2016,31(02):87.[doi:10.3969/j.issn.16717-414.2016.04.023]
[4]郭进京,胡林辉,陶千山,等.红细胞分布宽度在多发性骨髓瘤患者预后分期中的价值[J].现代检验医学杂志,2017,32(03):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
　GUO Jin-jing,HU Lin-hui,TAO Qian-shan,et al.Value of Red Cell Distribution Width in the Prognosis of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(02):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
[5]谭 奎,沈婵娟,张 玲,等.多发性骨髓瘤患者骨髓CD269和CD317基因的差异性表达研究[J].现代检验医学杂志,2017,32(06):64.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　TAN Kui,SHEN Chan-juan,ZHANG Ling,et al.Differential Expression of CD269 and CD317 Genes in Bone Marrow of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(02):64.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[6]盘国雄,谭才燕,何嘉颖,等.多发性骨髓瘤患者血清中lncRNA PCAT-1的表达水平与临床预后研究[J].现代检验医学杂志,2018,33(01):72.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　PAN Guo-xiong,TAN Cai-yan,HE Jia-ying,et al.Serum LncRNA PCAT-1 Expression Level of Patients with Multiple Myeloma and Clinical Value[J].Journal of Modern Laboratory Medicine,2018,33(02):72.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[7]刘玉霞,胡国瑜,袁朝晖,等.CD269和CD317在多发性骨髓瘤中的表达及临床意义[J].现代检验医学杂志,2018,33(02):58.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　LIU Yu-xia,HU Guo-yu,YUAN Chao-hui,et al.Expression of CD269 and CD317 in Multiple Myeloma and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2018,33(02):58.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[8]张 蓉,李国辉,刘小五,等.初诊多发性骨髓瘤患者外周血淋巴细胞绝对值/ 单核细胞绝对值比值在预测临床预后的价值研究[J].现代检验医学杂志,2020,35(01):101.[doi:10.3969/j.issn.1671-7414.2020.01.027]
　ZHANG Rong,LI Guo-hui,LIU Xiao-wu,et al.Value of Peripheral Blood Lymphocyte Absolute Value/Monocyte Absolute Value Ratio in Predicting Clinical Prognosis of Newly Diagnosed MultipleMyeloma Patients[J].Journal of Modern Laboratory Medicine,2020,35(02):101.[doi:10.3969/j.issn.1671-7414.2020.01.027]
[9]霍 豆,秦 爽,吴永昌,等.血清总轻链与游离轻链定量检测在多发性骨髓瘤诊断中的临床价值探讨[J].现代检验医学杂志,2020,35(04):87.[doi:10.3969/j.issn.1671-7414.2020.04.021]
　HUO Dou,QIN Shuang,WU Yong-chang,et al.Clinical Value of Quantitative Detection of sTLC and sFLC in Diagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2020,35(02):87.[doi:10.3969/j.issn.1671-7414.2020.04.021]
[10]何　进,张　艳,申娴娟,等.多发性骨髓瘤患者血清可溶性PD-L1水平在辅助诊断及临床分型的价值研究[J].现代检验医学杂志,2021,36(02):15.[doi:doi:10.3969/j.issn.1671-7414.2021.02.004]
　HE Jin,ZHANG Yan,SHEN Xian-juan,et al.Value of Blood Soluble PD-L1 in the Auxiliary Diagnosis and Clinical Subtype of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2021,36(02):15.[doi:doi:10.3969/j.issn.1671-7414.2021.02.004]

备注/Memo

备注/Memo:
基金项目：安徽省卫生健康委科研立项项目：AHWJ2020b0057。
作者简介：李洁茹（1992-），女，硕士，主治医师，研究方向：血液系统疾病的诊断及治疗，E-mail：15855518823@163.com。
更新日期/Last Update: 2025-03-15